

Marc Y Donath

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3900675/marc-y-donath-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

98
papers

13,934
citations

44
h-index

107
g-index

107
ext. papers

16,182
ext. citations

13.3
avg, IF

6.77
L-index

#	Paper	IF	Citations
98	Inflammation in obesity, diabetes, and related disorders.. <i>Immunity</i> , 2022 , 55, 31-55	32.3	28
97	L'inflammation dans la physiopathologie et le traitement du diabète de type 2 et de ses complications. <i>Medecine Des Maladies Metaboliques</i> , 2021 , 15, 661-661	0.1	
96	IL-1beta promotes the age-associated decline of beta cell function. <i>IScience</i> , 2021 , 24, 103250	6.1	1
95	Model-Based Assessment of C-Peptide Secretion and Kinetics in Post Gastric Bypass Individuals Experiencing Postprandial Hyperinsulinemic Hypoglycemia. <i>Frontiers in Endocrinology</i> , 2021 , 12, 611253	5.7	0
94	Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes?. <i>Cell Metabolism</i> , 2021 , 33, 2-4	24.6	7
93	IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis. <i>Metabolites</i> , 2021 , 11,	5.6	1
92	Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study. <i>Diabetes Therapy</i> , 2021 , 12, 943-954	3.6	5
91	Predictors of Postprandial Hypoglycemia After Gastric Bypass Surgery: a Retrospective Case-Control Study. <i>Obesity Surgery</i> , 2021 , 31, 2497-2502	3.7	1
90	Postprandial Hypoglycemia in Patients after Gastric Bypass Surgery Is Mediated by Glucose-Induced IL-1β <i>Cell Metabolism</i> , 2020 , 31, 699-709.e5	24.6	9
89	Response to Comment on Trinh et al. Successful Treatment of Immune Checkpoint Inhibitor-Induced Diabetes With Infliximab. <i>Diabetes Care</i> 2019;42:e153-e154. <i>Diabetes Care</i> , 2020 , 43, e11	14.6	2
88	Distinct Transcriptional Responses across Tissue-Resident Macrophages to Short-Term and Long-Term Metabolic Challenge. <i>Cell Reports</i> , 2020 , 30, 1627-1643.e7	10.6	19
87	Inhibition of IL-1beta improves Glycaemia in a Mouse Model for Gestational Diabetes. <i>Scientific Reports</i> , 2020 , 10, 3035	4.9	10
86	GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study. <i>Diabetologia</i> , 2020 , 63, 362-373	10.3	19
85	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. <i>Lancet, The</i> , 2020 , 396, 267-276	40	20
84	Evidence for cephalic phase insulin release in humans: A systematic review and meta-analysis. <i>Appetite</i> , 2020 , 155, 104792	4.5	5
83	Patient involvement to inform the design of a clinical trial in postbariatric hypoglycaemia. <i>BMC Medical Research Methodology</i> , 2020 , 20, 290	4.7	0
82	IL (Interleukin)-1 Receptor Antagonist Increases Ang (Angiotensin [1-7]) and Decreases Blood Pressure in Obese Individuals. <i>Hypertension</i> , 2020 , 75, 1455-1463	8.5	7

81	Treatment of Primary Aldosteronism With mTORC1 Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 4703-4714	5.6	2
80	Targeting innate immune mediators in type 1 and type 2 diabetes. <i>Nature Reviews Immunology</i> , 2019 , 19, 734-746	36.5	117
79	Designer cytokine for the treatment of diabetes. <i>Nature Metabolism</i> , 2019 , 1, 933-934	14.6	
78	Exercise upregulates copeptin levels which is not regulated by interleukin-1. <i>PLoS ONE</i> , 2019 , 14, e0217800	3.7	9
77	Exercise and the dipeptidyl-peptidase IV inhibitor sitagliptin do not improve beta-cell function and glucose homeostasis in long-lasting type 1 diabetes-A randomised open-label study. <i>Endocrinology, Diabetes and Metabolism</i> , 2019 , 2, e00075	2.7	2
76	Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease. <i>Endocrine Reviews</i> , 2019 , 40, 1080-1091	27.2	38
75	Effects of interleukin-1 antagonism on cortisol levels in individuals with obesity: a randomized clinical trial. <i>Endocrine Connections</i> , 2019 , 8, 701-708	3.5	3
74	SAT-382 Glucocorticoid Tapering in Monthly 1-mg Decrements Does Not Result in Clinically Manifest Adrenal Insufficiency in Patients with Rheumatoid Arthritis: Learnings from the Phase 3/4 SEMIRA Study. <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	78
73	SAT-059 Treatment Of Primary Aldosteronism With The mTORC1 Inhibitor Everolimus. <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	78
72	SAT-066 Effect Of Interleukin-1-receptor Antagonist On Hemodynamics And Renin-angiotensin-aldosterone System In Obese Individuals. <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	78
71	OP0030 RANDOMIZED CONTROLLED 24-WEEK TRIAL EVALUATING THE SAFETY AND EFFICACY OF BLINDED TAPERING VERSUS CONTINUATION OF LONG-TERM PREDNISONE (5 MG/D) IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVED LOW DISEASE ACTIVITY OR REMISSION ON TOCILIZUMAB 2019 ,		4
70	Successful Treatment of Immune Checkpoint Inhibitor-Induced Diabetes With Infliximab. <i>Diabetes Care</i> , 2019 , 42, e153-e154	14.6	22
69	Proteomic Landscape of Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2019 , 73, 469-480	8.5	14
68	The role of IL-1 in postprandial fatigue. <i>Molecular Metabolism</i> , 2018 , 12, 107-112	8.8	8
67	Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs Cell Proliferation and Insulin Secretion. <i>Cell Reports</i> , 2018 , 22, 1774-1786	10.6	37
66	First Experiences With a Wearable Multisensor in an Outpatient Glucose Monitoring Study, Part I: The Users' View. <i>Journal of Diabetes Science and Technology</i> , 2018 , 12, 562-568	4.1	13
65	Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2392-2401	15.1	170
64	IL-6-Type Cytokine Signaling in Adipocytes Induces Intestinal GLP-1 Secretion. <i>Diabetes</i> , 2018 , 67, 36-45	0.9	27

63	First Experiences With a Wearable Multisensor Device in a Noninvasive Continuous Glucose Monitoring Study at Home, Part II: The Investigators' View. <i>Journal of Diabetes Science and Technology</i> , 2018 , 12, 554-561	4.1	18
62	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet, The</i> , 2018 , 391, 319-328	4.0	43 ⁰
61	IL-1 Antagonism in Men With Metabolic Syndrome and Low Testosterone: A Randomized Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 3466-3476	5.6	21
60	Postprandial macrophage-derived IL-1 β stimulates insulin, and both synergistically promote glucose disposal and inflammation. <i>Nature Immunology</i> , 2017 , 18, 283-292	19.1	194
59	Interleukin-1 Antagonism Decreases Cortisol Levels in Obese Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1712-1718	5.6	16
58	Pancreatic β Cell-Derived Glucagon-Related Peptides Are Required for β Cell Adaptation and Glucose Homeostasis. <i>Cell Reports</i> , 2017 , 18, 3192-3203	10.6	6 ⁰
57	Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017 , 390, 1833-1842	4.0	634
56	IKK β inhibition prevents fat-induced beta cell dysfunction in vitro and in vivo in rodents. <i>Diabetologia</i> , 2017 , 60, 2021-2032	10.3	6
55	A guiding map for inflammation. <i>Nature Immunology</i> , 2017 , 18, 826-831	19.1	284
54	The Role of Inflammation in β Cell Dedifferentiation. <i>Scientific Reports</i> , 2017 , 7, 6285	4.9	84
53	Interleukin-33-Activated Islet-Resident Innate Lymphoid Cells Promote Insulin Secretion through Myeloid Cell Retinoic Acid Production. <i>Immunity</i> , 2017 , 47, 928-942.e7	32.3	86
52	Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications. <i>Diabetes Care</i> , 2016 , 39 Suppl 2, S244-52	14.6	134
51	Multiple benefits of targeting inflammation in the treatment of type 2 diabetes. <i>Diabetologia</i> , 2016 , 59, 679-82	10.3	7 ⁰
50	Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by β Cells. <i>Gastroenterology</i> , 2016 , 151, 165-79	13.3	49
49	Development of an Interleukin-1 β Vaccine in Patients with Type 2 Diabetes. <i>Molecular Therapy</i> , 2016 , 24, 1003-12	11.7	43
48	Angiotensin II induces interleukin-1 β mediated islet inflammation and β cell dysfunction independently of vasoconstrictive effects. <i>Diabetes</i> , 2015 , 64, 1273-83	0.9	38
47	The Effect of a Global, Subject, and Device-Specific Model on a Noninvasive Glucose Monitoring Multisensor System. <i>Journal of Diabetes Science and Technology</i> , 2015 , 9, 865-72	4.1	18
46	The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications. <i>Trends in Endocrinology and Metabolism</i> , 2015 , 26, 551-563	8.8	112

45	Muscle-Derived IL-6 Is Not Regulated by IL-1 during Exercise. A Double Blind, Placebo-Controlled, Randomized Crossover Study. <i>PLoS ONE</i> , 2015 , 10, e0139662	3.7	5
44	Safety, pharmacokinetics, and preliminary efficacy of a specific anti-IL-1alpha therapeutic antibody (MABp1) in patients with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 955-60	3.2	15
43	Interleukin-1 receptor antagonist: friend or foe to the heart?. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 228-9	18.1	13
42	Targeting 12-lipoxygenase as a novel strategy to combat the effects of inflammation on beta cells in diabetes. <i>Diabetologia</i> , 2015 , 58, 425-8	10.3	9
41	What is the role of autoimmunity in type 1 diabetes? A clinical perspective. <i>Diabetologia</i> , 2014 , 57, 653-5	10.3	31
40	Targeting inflammation in the treatment of type 2 diabetes: time to start. <i>Nature Reviews Drug Discovery</i> , 2014 , 13, 465-76	64.1	465
39	Interleukin-6 contributes to early fasting-induced free fatty acid mobilization in mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2014 , 306, R861-7	3.2	36
38	Fractalkine (CX3CL1), a new factor protecting β cells against TNF. <i>Molecular Metabolism</i> , 2014 , 3, 731-41	8.8	23
37	A role for interleukin-22 in the alleviation of metabolic syndrome. <i>Nature Medicine</i> , 2014 , 20, 1379-81	50.5	13
36	Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. <i>Cell Metabolism</i> , 2013 , 17, 860-872	24.6	222
35	Identification of a SIRT1 mutation in a family with type 1 diabetes. <i>Cell Metabolism</i> , 2013 , 17, 448-455	24.6	83
34	Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. <i>Lancet, The</i> , 2013 , 381, 1905-15	40	234
33	Susceptibility to fatty acid-induced β cell dysfunction is enhanced in prediabetic diabetes-prone biobreeding rats: a potential link between β cell lipotoxicity and islet inflammation. <i>Endocrinology</i> , 2013 , 154, 89-101	4.8	28
32	Infliximab in the treatment of Crohn disease and type 1 diabetes. <i>Diabetes Care</i> , 2013 , 36, e90-1	14.6	17
31	GLP-1 effects on islets: hormonal, neuronal, or paracrine?. <i>Diabetes Care</i> , 2013 , 36 Suppl 2, S145-8	14.6	51
30	Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. <i>Diabetes Care</i> , 2012 , 35, 1654-62	14.6	205
29	Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. <i>Nature Medicine</i> , 2011 , 17, 1481-9	50.5	581
28	Type 2 diabetes as an inflammatory disease. <i>Nature Reviews Immunology</i> , 2011 , 11, 98-107	36.5	2207

27	Characteristics of a multisensor system for non invasive glucose monitoring with external validation and prospective evaluation. <i>Biosensors and Bioelectronics</i> , 2011 , 26, 3794-800	11.8	44
26	Inhibition of IL-1beta improves fatigue in type 2 diabetes. <i>Diabetes Care</i> , 2011 , 34, e158	14.6	43
25	Inflammation as a sensor of metabolic stress in obesity and type 2 diabetes. <i>Endocrinology</i> , 2011 , 152, 4005-6	4.8	29
24	IL-1 β activation as a response to metabolic disturbances. <i>Cell Metabolism</i> , 2010 , 12, 427-8	24.6	7
23	Cytokine production by islets in health and diabetes: cellular origin, regulation and function. <i>Trends in Endocrinology and Metabolism</i> , 2010 , 21, 261-7	8.8	166
22	Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. <i>Diabetologia</i> , 2010 , 53, 1795-806	10.3	172
21	Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. <i>Diabetes Care</i> , 2009 , 32, 1663-8	14.6	313
20	Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. <i>Physiology</i> , 2009 , 24, 325-31	9.8	218
19	Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. <i>Endocrinology</i> , 2009 , 150, 5218-29	4.8	244
18	Pancreatic islet inflammation in type 2 diabetes: from alpha and beta cell compensation to dysfunction. <i>Archives of Physiology and Biochemistry</i> , 2009 , 115, 240-7	2.2	73
17	Interleukin-6 regulates pancreatic alpha-cell mass expansion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 13163-8	11.5	193
16	Cytokines and beta-cell biology: from concept to clinical translation. <i>Endocrine Reviews</i> , 2008 , 29, 334-50	27.2	171
15	Islet inflammation in type 2 diabetes: from metabolic stress to therapy. <i>Diabetes Care</i> , 2008 , 31 Suppl 2, S161-4	14.6	240
14	Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 4065-74	5.6	239
13	Interleukin-1-receptor antagonist in type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , 2007 , 356, 1517-26	59.2	1355
12	The Fas pathway is involved in pancreatic beta cell secretory function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 2861-6	11.5	64
11	Increased number of islet-associated macrophages in type 2 diabetes. <i>Diabetes</i> , 2007 , 56, 2356-70	0.9	515
10	Multisensor Concept for non-invasive Physiological Monitoring. <i>Conference Record - IEEE Instrumentation and Measurement Technology Conference</i> , 2007 ,		3

9	Type 1, type 1.5, and type 2 diabetes: NOD the diabetes we thought it was. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 12217-8	11.5	31
8	Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets. <i>Diabetes</i> , 2006 , 55, 2713-22	0.9	139
7	Mechanisms of beta-cell death in type 2 diabetes. <i>Diabetes</i> , 2005 , 54 Suppl 2, S108-13	0.9	339
6	Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 8138-43	11.5	211
5	Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. <i>Journal of Molecular Medicine</i> , 2003 , 81, 455-70	5.5	330
4	FLIP switches Fas-mediated glucose signaling in human pancreatic beta cells from apoptosis to cell replication. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 8236-41	11.5	122
3	Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. <i>Journal of Clinical Investigation</i> , 2002 , 110, 851-60	15.9	439
2	Glucose-induced cell production of IL-1 contributes to glucotoxicity in human pancreatic islets. <i>Journal of Clinical Investigation</i> , 2002 , 110, 851-860	15.9	846
1	Insulin-like growth factor I: an attractive option for chronic heart failure?. <i>Drugs and Aging</i> , 1999 , 15, 251-4	4.7	4